Monday 14 October
14h30: Inaugural conference Ad.P. Ijzerman (Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands): Kinotyping GPCRs – why IC50 values are so …
Session 1: Signaling
15h15: Giovanni Marsicano (Neurocentre Magendie, INSERM U862, Bordeaux): Cannabinoid receptor CB1 signaling in the brain: the where matters.
16h30: Ralf Jockers (Institut Cochin, Paris): Hetero-oligomeric MT1/MT2 melatonin receptors and photoreceptor function.
16h50: Lauriane Bray (Institut de Pharmacologie et de Biologie Structurale, Toulouse): Identification of post-translational modifications (phosphorylation) involved in the regulation of NPFF2 receptor activity.
17h05: Marjorie Damian (Institut des Biomolécules Max Mousseron, Montpellier): Heterodimerization with its splice variant blocks the ghrelin receptor 1a in a non-signaling conformation.
17h20: Charlotte Avet (Unité de Biologie Fonctionelle et Adaptative, Paris): GnRH receptor signals through its first intracellular domain to couple to calcium and cAMP signaling pathways. Role of the accessory protein SET.
18h00: poster session (odd numbers)
Tuesday 15 October
Session 2: New approaches in GPCR studies
9h00: Martin Lohse (University of Würzburg, Germany): Single molecule studies of GPCRs and their signaling
9h45: Jan Steyaert (Free University of Brussels, Belgium): Nanobodies to study GPCR transmembrane signaling: from structure to function to drugs.
11h00: Daniel Fourmy (Université Paul Sabatier, Toulouse):Targeting a G-protein coupled receptor overexpressed in endocrine tumors by magnetic nanoparticles to induce cell death
11h20: Coralie Martin (Muséum Histoire Naturelle, Paris, France): The CXCL12/CXCR4 chemokine GPCR axis in the filariasis development and as a host susceptibility factor for the nematode pathogenesis
11h40: Julie Kniazeff (Institut de Génomique Fonctionelle, Montpellier): GABA-B receptor oligomers: allostery, stability and modulation
11h55: Katarzyna Niescierowicz (Institut de Biologie Structurale, Grenoble): Ion Channel-Coupled Receptors as the tool for GPCR’ cholesterol-sensitivity screening.
Session 3: Discovery of innovative GPCR ligands
14h00: Catherine LLorens-Cortes (Collège de France, Paris, France): The apelin receptor: from ligand discovery to physiological role
14h45: Caterina Bissantz (F. Hoffmann-La Roche AG, Basel, Switzerland): Impact of GPCR modeling on drug design - the example of NK3 antagonists and GPBAR1 agonists
15h30: Nicolas Renault (Faculté des Sciences Pharmaceutiques et Biologiques, Lille): Activation of the MT2 melatonin receptor
16h20: Jérôme Leprince (Faculté des Sciences, Rouen): Molecular basis of agonist docking in a human GPR103 homology model: site-directed mutagenesis and structure-activity relationship studies
16h40: Christelle Doebelin (Laboratoire d'Innovation Thérapeutique, Illkirch): Pallado-catalyzed reactions applied to solid phase synthesis of dipeptidic GPR54 agonists
16h55: Bruno Commare (Laboratoire de Chimie & Biologie Pharmacologiques et Toxicologiques, Paris): Design and synthesis of metabotropic glutamate receptor agonists
17h10: General assembly of GDR members
18h00: poster session (even numbers)
Wednesday 16 October
Session 4: Pathophysiology
9h00: Brigitte Kieffer (IGBMC, Strasbourg, France): In vivo approaches for GPCR function.
9h45: Angela Sirigu (IUMR 5229 CNRS UCB Lyon 1, Bron, France): Brain and behavioral mechanisms of oxytocin
11h00: Cyril Goudet (Institut de Génomique Fonctionnelle, Montpellier, France):” Alleviating pain hypersensitivity through activation of type 4 metabotropic glutamate receptor’
11h20: Christian Gachet (INSERM U949 – Etablissemnt Français du Sang, Strasbourg, France): Multiples roles of the P2Y1 receptor in platelet activation, vascular inflammation and atherosclerosis.
11h40: Elise Orhan (Institut de la Vision, Paris, France): Elucidation of physiopathological mechanisms of GPR179
11h55: Aurélie Borrull (CEA, iBiTec-S/SPI, 91191 Gif sur Yvette, France):Development of new monoclonal antibodies against the native conformation of human endothelin receptors, overexpressed in many cancers.
12h15: - Awards – Conclusions
Please note that you can also register to our first workshop!